What Sirio Pharma does

Sirio Pharma Co., Ltd. (仙乐健康) is a China-based, Shenzhen-listed (300791.SZ) contract development and manufacturing organization (CDMO) specializing in nutritional health products for global brand owners. Founded in 1993 in Shantou and now operating seven automated production facilities across China (Shantou, Ma'anshan, Zhuhai), the United States (City of Industry, Huntington Beach via Best Formulations), and Germany (Pritzwalk via Ayanda), plus an APAC hub in Singapore and a Thailand facility under construction in 2025, SIRIO serves over 400 brand partners in 50+ countries and was the first Chinese CDMO to list on China's A-share market (2019).

The company's technology platform spans six classic dosage forms (softgels, gummies, liquids, tablets, powders, capsules) and six innovative formats including Plantegrity® plant-based softgels, Lifechews® gel tablets (with patented micronized lipid carrier technology delivering 6.75x bioavailability), ProbioArk™ probiotic droplets, Casing Gummies, YuePei™ popping droplets, and milky beverages. R&D is anchored by five global centers, 107 invention patents (Chinese, Australian, Japanese, Canadian), 6,000+ mature formulations, and a 2024 R&D investment exceeding CNY 100 million. Recent additions include an E-Cube bioinspired efficacy platform and a DeepSeek-powered intelligent formulation design system launched in 2025.

SIRIO generates revenue through professional services / contract manufacturing fees paid by brand owners and finished-product companies, with regional sales coverage in CN/APAC, Europe, and the Americas. The company operates a B2B model with direct enterprise sales teams, generates revenue per project across the value chain (concept development, formulation, regulatory support, manufacturing, packaging), and pursues certifications including FDA, NSF GMP, TGA, BRCGS, ISO 9001/14001/27001/45001/50001, USDA Organic, EU Organic, Kosher, and Halal. End-markets span cardiovascular, gut health, bone and joint, beauty, immune support, healthy aging, and life-stage nutrition, with newer verticals in pet nutrition and anti-aging research.

Name

Sirio Pharma

Legal name

Sirio Pharma Co., Ltd.

Website

https://siriopharma.com

Company type

Public

Founded year

1993

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Sirio Pharma (仙乐健康) is a Shenzhen-listed Chinese CDMO that develops and manufactures nutritional supplements across softgels, gummies, liquids, tablets, powders, and capsules for 400+ global brand partners in 50+ countries, operating seven automated production facilities across China, the US, and Europe.

Ownership category

akta.pro rank

Product category

Nutritional Supplement CDMO

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)

akta.pro secondary industries

Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL)

Keywords

• Nutritional supplements manufacturing
• Contract development manufacturing
• Dietary supplement CDMO
• Nutraceutical formulations
• Softgel and gummy production

Headquarters

HQ city

Shantou

HQ country

China

HQ region

Asia

Offices11 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Contract Manufacturing Services: CDMO model providing contract development and manufacturing services for nutritional health products including softgels, gummies, liquids, tablets, powders, and capsules to brand owners and finished product companies globally.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

Sirio Pharma is a global Contract Development and Manufacturing Organization (CDMO) for nutritional health products, offering end-to-end services from concept development and customized formulation R&D to large-scale manufacturing and packaging across multiple dosage forms including softgels, gummies, liquids, tablets, powders, and capsules. The company manufactures dietary supplements and personal care products for brand owners and finished-product companies, operating seven automated production facilities and five R&D centers across China, the United States, and Europe.

Product overview

Sirio Pharma is a globally recognized CDMO (Contract Development and Manufacturing Organization) specializing in nutritional health products. The company operates as a unified platform offering end-to-end solutions from concept to market, encompassing market insights, customized solutions, differentiated R&D, global manufacturing, and marketing support. The product portfolio includes six classic dosage forms (Softgels, Gummies, Liquids, Tablets, Powders, Capsules) and six innovative dosage forms (Plantegrity® Plant-based Softgels, Lifechews® Gel Tablets, ProbioArk™ Droplet, Casing Gummies, YuePei™ Popping Droplet, Milky Beverages). Products span key wellness categories including Beauty and Wellness, Gut Health, Bone and Joint Health, Immune Support, Cardiovascular and Metabolic Health, and Healthy Ageing. The company also offers proprietary technology platforms including E-Cube Bioinspired Efficacy Technology Platform and DeepSeek AI-powered Intelligent Formulation Design System.

Differentiator

Problem solved

Functional benefit

Brands

• Plantegrity®: Plant-based softgels with exceptional heat resistance and enteric coating options (EnteriClear™)
• Lifechews®
• ProbioArk™
• Cui Yi Qiu®
• Casing Gummies
• YuePei™
• Milky Beverages
• GummyPlus®
• LifeBites™
• PuraColla®
• SlimBoom®
• Freshmega®
• Puremega®
• Weituoli®
• NuPalette™
• GummiBiotics™
• Briveal®

Quantifiable outcome

• 6000+ mature formulations developed for global clients
• +5 more outcomes

Named customers1 record

Segments7 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature8 records

Partnerships

13 partnerships are on record, tiered core and minor.

• China Agricultural UniversitycoreStrategic or Co-development Partner · 31 March 2023SIRIO is the sole corporate participant in the national research initiative 'Health Regulation of Food Components on the Digestive System and Intestinal Homeostasis' led by China Agricultural University in partnership with ten prominent institutions. SIRIO leads two sub-projects focusing on essential micronutrients in digestive health and precision dietary intervention for young children.
• Best Formulations LLCcoreStrategic or Co-development Partner · 10 January 2023Sirio Pharma acquired a 70% stake in Best Formulations LLC in January 2023. Best Formulations is a leading manufacturer in the nutritional health industry based in California, serving as a critical driver of SIRIO's deepening presence in the nutritional health space and extending SIRIO's reach to the U.S. West Coast, creating a synchronized tri-regional production network across Asia, the United States, and Europe.
• Ayanda GmbH (now Sirio Pharma Germany)coreStrategic or Co-development Partner · 1 January 2016Acquired Ayanda GmbH in 2016, now operating as Sirio Pharma Germany. The Pritzwalk facility serves as SIRIO's European headquarters and one of Europe's leading softgel manufacturers, providing comprehensive end-to-end solutions across the European market.
• Chinese Institute of Food Science and Technology (CIFST)coreStrategic or Co-development PartnerCo-founded the CIFST-SIRIO Nutrition, Health & Food Technology Innovation Fund supporting a three-year program focused on frontier topics in nutrition and health. Through phased funding, the initiative advances breakthrough technologies and accelerates translation of research into practical applications.
• Chinese Nutrition SocietyminorOthersIndustry partner relationship for nutrition science collaboration and industry development.
• China Nutrition and Health Food AssociationminorOthersIndustry partner relationship supporting nutrition and health food industry standards and development.
• State Administration for Market RegulationminorOthersRegulatory partnership for compliance and standards development in China's health food sector.
• Complementary Medicines Australia (CMA)minorOthersPartnership with Australian complementary medicines industry association for regional market development.
• Nutrition Business Journal (NBJ)minorOthersIndustry media and research partnership for market intelligence and industry insights.
• Council for Responsible Nutrition (CRN)minorOthersPartnership with U.S. dietary supplement industry trade association.
• United States Pharmacopeia (USP)coreOthersSIRIO is the first Chinese company to contribute to USP gummy standards development. SIRIO's standard for Ubidecarenone Chewable Gels was included in the United States Pharmacopeia.
• British Retail Consortium (BRC)minorOthersGlobal food safety standards partnership for manufacturing quality assurance.
• SupplySide (North America)minorOthersActive participation in SupplySide West exhibitions as both exhibitor and keynote speaker to showcase gummy supplement innovations and manufacturing capabilities to North American market.

Scale indicators20 records

Recent moves11 records

Expansion highlights6 records

Direct peers

• Aenova Group: German-headquartered CDMO offering solid, semi-solid, and liquid dosage forms including softgels for pharmaceutical and nutraceutical brand owners across Europe. Highly comparable to Sirio's Pritzwalk softgel operations and complementary in cross-regional sourcing strategies.
• Procaps Group: Latin American integrated pharmaceutical and nutraceutical CDMO with softgel, capsule, and complex formulation capabilities serving global brand owners. Comparable to Sirio in CDMO model, dosage-form breadth, and emerging-market-export orientation.
• Robinson Pharma: U.S.-based contract manufacturer of dietary supplements including softgels, tablets, capsules, and powders serving North American brand customers. Closely comparable to Sirio's Best Formulations subsidiary and competes for similar U.S. brand-owner projects.
• TCI Bio: Taiwan-based CDMO specializing in nutritional supplements, gummies, and functional foods for global brands. Comparable Asian-region nutraceutical CDMO with similar dosage-form portfolio and export-led business model.
• CapsCanada: Canadian manufacturer specializing in softgel capsules for pharmaceutical and nutraceutical applications. Directly comparable to Sirio's softgel-centric operations, particularly the Pritzwalk facility, and competes for North American and European softgel contracts.
• Hermes Arzneimittel: European pharmaceutical and nutraceutical manufacturer with significant softgel production capacity serving brand customers. Comparable in dosage-form specialization and European market positioning to Sirio's German operations.
• Pharma Tech Industries: U.S.-based contract manufacturer and packager of powders, tablets, capsules, and teas for the nutritional supplement industry. Comparable mid-sized CDMO serving similar U.S. brand-owner customers with contract manufacturing and packaging services.

Broad incumbents

• Catalent: One of the largest global CDMOs with broad pharmaceutical and consumer health capabilities including softgels and oral dose technologies. Overlaps with Sirio in dosage-form services but operates at much larger scale across pharma, biologics, and consumer health.
• Recipharm: European CDMO offering solid, semi-solid, and sterile dosage forms for pharma and consumer health. Comparable in offering integrated CDMO services to European customers but with a stronger pharmaceutical bias than Sirio's nutraceutical focus.

Others

• Lonza Group: Swiss-headquartered global CDMO dominant in biologics, small molecules, and nutritional ingredients. Competes with Sirio for nutritional ingredient and finished dose projects but at far broader scale and deeper pharmaceutical focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/siriopharma

Compliance27 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sirio Pharma